SPOTLIGHT: Symphogen pockets $25M
Danish biotech Symphogen has rounded up $25 million in its fourth round of venture capital, with Takeda Research Investment joining the investment group. Symphogen has a lead candidate now poised to enter the clinic and three other projects in earlier stages. Symphogen also has a few out-licensing deals in the works, telling BioWorld it expects to have two deals inked this year. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
